Last reviewed · How we verify

Non-selective NSAIDS

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · FDA-approved active Small molecule

Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Rheumatoid arthritis, Osteoarthritis.

At a glance

Generic nameNon-selective NSAIDS
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug classNon-selective NSAID
TargetCOX-1 and COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Rheumatology, Cardiovascular
PhaseFDA-approved

Mechanism of action

Non-selective NSAIDs block cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins—key mediators of inflammation, pain, and fever. By inhibiting both COX-1 and COX-2 isoforms, these drugs reduce prostaglandin levels systemically. This broad inhibition provides analgesic and anti-inflammatory effects but also increases the risk of gastrointestinal and cardiovascular adverse events compared to selective COX-2 inhibitors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: